V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016641 | 160008251 | 1.78 | 84.6 | Disease modification (D) | 2015-07-24 | 2015-08-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100119618 |
| 160016643 | 160008252 | 1.83 | 83 | Neo-adjuvant (N) | 2018-02-11 | 2018-02-22 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101340545 |
| 160016644 | 160008253 | 1.62 | 73 | Curative (C) | 2018-12-19 | 2018-12-19 | Doxorubicin 75mg/m2 | 02 | null | DOXORUBICIN | 101692033 |
| 160016646 | 160008254 | 1.65 | 0 | Palliative (P) | 2019-06-17 | 2019-07-05 | CARBOPLATIN + PACLITAXEL | N | N | CARBOPLATIN + PACLITAXEL | 100730705 |
| 160016649 | 160008255 | 1.62 | 64.5 | null | 2017-05-07 | 2017-05-07 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | DOXORUBICIN + OLARATUMAB | 100325428 |
| 160016655 | 160008256 | 1.63 | 79.6 | Palliative (P) | 2019-09-11 | 2019-09-12 | DOXORUBICIN | 02 | N | DOXORUBICIN + OLARATUMAB | 100203446 |
| 160016657 | 160008257 | 1.78 | 69 | Curative (C) | 2018-12-27 | 2019-01-19 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 101570378 |
| 160016659 | 160008258 | 1.75 | 63 | Palliative (P) | 2017-05-01 | 2017-05-10 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101744719 |
| 160016660 | 160008259 | 1.7 | 91 | Curative (C) | 2022-01-06 | 2022-01-31 | PACLITAXEL | 02 | N | IVA | 101339215 |
| 160016662 | 160008260 | 1.68 | 82.5 | Palliative (P) | null | 2017-11-03 | Bevacizumab 7.5mg/kg | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101470002 |
| 160016666 | 160008261 | 1.48 | 88.8 | Neo-adjuvant (N) | 2018-06-22 | 2018-07-26 | EW EuroEwing 2012 Arm A VIDE | N | N | TRIAL UNSPECIFIED | 101163761 |
| 160016669 | 160008262 | 1.72 | 70.2 | Palliative (P) | 2017-12-07 | 2017-12-10 | EW EuroEwing 2012 Arm B VDC | 02 | null | NOT MATCHED | 101742044 |
| 160016670 | 160008263 | 1.64 | 60.2 | Palliative (P) | 2019-04-30 | 2019-04-30 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101081296 |
| 160016671 | 160008264 | 1.73 | 69.3 | Palliative (P) | 2019-09-30 | 2019-10-08 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | CARBOPLATIN + GEMCITABINE | 100844767 |
| 160016673 | 160008265 | 1.7 | 62.2 | Curative (C) | 2017-08-01 | 2017-08-02 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100373804 |
| 160016675 | 160008266 | 1.79 | 68 | Palliative (P) | null | 2019-09-19 | STS Rhabdomyosarco RMS 2005 IVADoVV | 01 | N | STS NON-RHABDO EPSSG 2005 IFOS DOX | 100872158 |
| 160016676 | 160008267 | 0 | 16.8 | null | 2022-01-08 | 2022-01-08 | EW EuroEwing 2012 Arm A VAC | null | Y | DOXORUBICIN + IFOSFAMIDE | 100425154 |
| 160016678 | 160008268 | 1.65 | 120 | Curative (C) | 2018-01-12 | 2018-01-15 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + OLARATUMAB | 100848983 |
| 160016681 | 160008269 | 1.72 | 91 | Neo-adjuvant (N) | null | 2016-05-17 | Doxorubicin + Olaratumab | N | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100640432 |
| 160016683 | 160008270 | 1.79 | 99 | Palliative (P) | 2017-09-14 | 2017-09-27 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101185224 |
| 160016684 | 160008271 | 1.65 | 72.8 | Palliative (P) | 2016-12-21 | 2016-12-31 | Carboplatin + Paclitaxel (weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101698013 |
| 160016686 | 160008272 | null | null | 03 | 2017-05-23 | 2017-05-27 | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 100022000 |
| 160016690 | 160008273 | 1.82 | 53.6 | Palliative (P) | null | 2019-07-29 | EW EuroEwing 2012 Arm A VAI | 02 | N | TRIAL UNSPECIFIED | 101122849 |
| 160016692 | 160008274 | 1.75 | 78 | Palliative (P) | 2020-03-06 | 2020-03-22 | Cisplatin + Pemetrexed | Y | null | CISPLATIN + PEMETREXED | 100161840 |
| 160016693 | 160008275 | 1.79 | 78.4 | Neo-adjuvant (N) | 2018-12-11 | 2018-12-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100996625 |
| 160016695 | 160008276 | 1.71 | 107 | Palliative (P) | 2018-06-01 | 2018-06-01 | Doxorubicin + Ifosfamide | N | N | DOXORUBICIN + IFOSFAMIDE | 100398565 |
| 160016696 | 160008277 | 1.75 | 88 | Curative (C) | null | 2019-09-18 | Doxorubicin 75mg/m2 | null | N | DOCETAXEL + GEMCITABINE | 101638226 |
| 160016697 | 160008278 | 1.72 | 64.2 | null | 2019-02-03 | 2019-02-26 | Doxorubicin + Ifosfamide | N | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101596376 |
| 160016698 | 160008279 | 1.6 | 76 | Neo-adjuvant (N) | 2019-10-28 | 2019-11-03 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100699335 |
| 160016701 | 160008280 | 1.6 | 72.2 | null | 2017-04-09 | 2017-04-10 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | N | null | BEVACIZUMAB + CARBO + PACLITAXEL | 100137788 |
| 160016703 | 160008281 | 1.84 | null | Curative (C) | null | 2019-04-06 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101594163 |
| 160016706 | 160008282 | 1.59 | 77 | Palliative (P) | 2019-06-06 | 2019-06-19 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 100928396 |
| 160016707 | 160008283 | null | 57.9 | Palliative (P) | 2019-05-14 | 2019-05-27 | Cyclophosphamide oral | null | null | PEMBROLIZUMAB | 100086975 |
| 160016710 | 160008284 | 1.67 | 84.7 | Palliative (P) | 2016-10-08 | 2016-10-29 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | CARBOPLATIN + PACLITAXEL | 100954690 |
| 160016711 | 160008285 | 1.86 | 96.4 | Adjuvant (A) | 2017-09-03 | 2017-09-24 | VINCRISTINE | 02 | N | CISPLATIN + GEMCITABINE | 100851842 |
| 160016712 | 160008286 | 1.77 | 81.6 | Palliative (P) | 2016-09-27 | 2016-09-28 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100683768 |
| 160016714 | 160008287 | 1.76 | 78 | Adjuvant (A) | 2018-09-12 | 2018-09-27 | EW EuroEwing 2012 Arm A VIDE | 02 | N | CARBOPLATIN + ETOPOSIDE | 100389479 |
| 160016717 | 160008289 | 0 | 17.6 | Palliative (P) | 2017-09-08 | 2017-09-19 | Liposomal Doxorubicin (20mg/m2) | 01 | N | IMATINIB | 101612845 |
| 160016718 | 160008290 | 1.83 | 64.3 | 03 | 2016-10-30 | 2016-11-11 | PACLITAXEL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100521302 |
| 160016720 | 160008291 | 0 | 18 | Neo-adjuvant (N) | 2018-04-29 | 2018-04-29 | Cetuximab + FOLFIRI cycle1 | null | N | DOXORUBICIN + IFOSFAMIDE | 100139404 |
| 160016721 | 160008292 | null | null | Adjuvant (A) | 2018-11-08 | 2018-11-16 | Doxorubicin + Ifosfamide | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 100121389 |
| 160016725 | 160008294 | 1.54 | 98.4 | Neo-adjuvant (N) | 2017-07-21 | 2017-07-21 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100950547 |
| 160016727 | 160008295 | 1.73 | 77 | null | 2018-06-16 | 2018-06-26 | Paclitaxel 7 day | 02 | N | LIPOSOMAL DOXORUBICIN | 100434959 |
| 160016728 | 160008296 | 1.78 | 91.2 | null | 2019-01-04 | 2019-01-16 | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 101189672 |
| 160016730 | 160008297 | 1.66 | 93.3 | Curative (C) | 2018-08-02 | 2018-09-18 | DOXORUBICIN | 02 | N | DOXORUBICIN + OLARATUMAB | 100155044 |
| 160016731 | 160008298 | 1.56 | 69.5 | Curative (C) | 2016-05-09 | 2016-05-23 | Pemetrexed | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101509788 |
| 160016732 | 160008299 | 1.78 | 86.8 | Palliative (P) | 2019-03-25 | 2019-04-18 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100892266 |
| 160016734 | 160008300 | 1.69 | 78 | Palliative (P) | 2018-02-12 | 2018-02-21 | Trial Unspecified | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100068510 |
| 160016738 | 160008301 | 1.68 | 71.15 | Palliative (P) | 2018-07-05 | 2018-07-21 | Doxorubicin 75mg/m2 | null | null | DOXORUBICIN | 101198025 |
| 160016739 | 160008302 | 1.56 | 60 | Palliative (P) | 2017-03-06 | 2017-03-12 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100911564 |